Sizzling Stock Alert – Exelixis, Inc.’s (EXEL)

 Exelixis, Inc.’s (EXEL)’s Stock Price Update:

Exelixis, Inc.’s (EXEL) stock price ended its day with a loss of -1.29% and finalized at the price of $11.52. During its last trading session, Stock traded with the total exchanged volume of 2.77 million shares. The average volume stands around 6.52 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 0.43. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Exelixis, Inc.’s (EXEL) is a part of Healthcare sector and belongs to Biotechnology industry.

USA based company, Exelixis, Inc.’s (EXEL)’s latest closing price distance was 57.64% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -5.68% and -11.94% compared with the 20 Day Moving Average.

Analysts’ mean recommendation for Exelixis, Inc.’s (EXEL) stands at 1.40. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

To review the EXEL previous performance, look at its past history, which highlighted below:

During last 5 trades the stock sticks almost -3.44%.

During last one month it showed the change of -18.64%.

During last 3 month it remained at 34.11%.

Along with these its year to date performance is standing at 104.26%.

ATR value of company was 0.80 and Relative Strength Index (RSI) was 39.36. The stock volatility for week was 4.86% while for month was 7.30%.The stock, as of last close, traded 224.51% to its 52 week low and was changed -26.06% from its 52 week high. Beta factor, which measures the riskiness of the security, was observed as 1.61. EXEL’s value Change from Open was at -1.54% with a Gap of 0.26%.

EPS growth in past 5 year was 0.90% along with sales growth of -27.50% in the last five years.

EPS growth in next year is estimated to reach 86.90% while EPS growth estimate for this year is set at 41.30%.

The price to sales ratio is 17.

FacebookTwitter

Leave a Reply

Your email address will not be published. Required fields are marked *